Download Image
    
Share
  
Post
Efzofitimod for COVID-19
1 study with 32 patients
Hospital Icon Control
Hospital Icon Efzofitimod Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Efzofitimod studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -291% Mortality -291% Hospitalization -24% RCTs -291% Late -291% Favorsefzofitimod Favorscontrol
Efzofitimod is an intravenously administered Fc-fusion biologic immunomodulator that binds neuropilin-2 to down-regulate inflammatory responses.
Oct 23
2020
 Walker et al., NCT04412668 A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
291% higher mortality (p=1), 24% longer hospitalization (p=0.53), and 11% worse recovery (p=1). RCT 32 hospitalized COVID-19 patients showing no significant differences with efzofitimod.